Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension

Basit Öğe Kaydı
dc.authorscopusid55408696100
dc.authorscopusid8615642100
dc.authorscopusid8650271300
dc.authorscopusid35274318900
dc.authorscopusid35274448800
dc.authorscopusid36105714600
dc.authorscopusid35338946100
dc.contributor.authorBulur, Serkan
dc.contributor.authorOzhan, Hakan
dc.contributor.authorErden, Ismail
dc.contributor.authorAlemdar, Recai
dc.contributor.authorAydin, Mesut
dc.contributor.authorCaglar, Onur
dc.contributor.authorBasar, Cengiz
dc.date.accessioned2024-09-25T19:43:07Z
dc.date.available2024-09-25T19:43:07Z
dc.date.issued2011
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractThe efficacy of olmesartan on fibrinolytic capacity has not been studied yet. Therefore, the aim of the present study was to investigate the efficacy of olmesartan on hemostatic/fibrinolytic status by measuring plasma level of plasminogen activator inhibitor-1 (PAI-1) and soluble thrombomodulin levels in patients with hypertension. Forty-two consecutive, newly diagnosed (25 women and 17 men with a mean age of 48 ± 8 years) patients with untreated essential hypertension were included in the study. Olmesartan medoxomil (20 mg/day) was started and the patients were followed up for 6 months. Baseline biochemical variables, thrombomodulin, and PAI-1 levels were compared with the levels of these variables measured at the end of the 6-month follow-up period. After 6 months of treatment with olmesartan medoxomil, there was a significant reduction in systolic and diastolic blood pressure (from 159.5 ± 10.9 to 134.6 ± 12.7 mmHg and from 98.0 ± 6.3 to 83.9 ± 7.0 mmHg, respectively). Mean plasma PAI-1 and thrombomodulin levels were also significantly decreased (59.73 ± 41.91 vs. 48.60 ± 33.65 ng/ml, P = 0.001 and 8.09 ± 2.29 vs. 6.92 ± 1.42 ?g/l, P < 0.001, respectively). Olmesartan medoxomil decreased plasma PAI-1 and thrombomodulin levels after 6 months of therapy, indicating a favorable effect on fibrinolytic capacity in patients with essential hypertension. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.en_US
dc.identifier.doi10.1097/MBC.0b013e328340aecf
dc.identifier.endpage33en_US
dc.identifier.issn0957-5235
dc.identifier.issue1en_US
dc.identifier.pmid20975532en_US
dc.identifier.scopus2-s2.0-78650794173en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage29en_US
dc.identifier.urihttps://doi.org/10.1097/MBC.0b013e328340aecf
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12445
dc.identifier.volume22en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofBlood Coagulation and Fibrinolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectfibrinolytic capacityen_US
dc.subjecthypertensionen_US
dc.subjectolmesartanen_US
dc.titleEfficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertensionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu